An Open-Label, Single Arm, Pilot Study of the Renal Safety of Everolimus in Addition to Neoral in Cardiac Transplant Recipients With Established Allograft Vasculopathy.
Phase of Trial: Phase III
Latest Information Update: 09 Jul 2010
At a glance
- Drugs Ciclosporin; Everolimus
- Indications Heart transplant rejection
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 09 Jul 2010 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
- 24 Dec 2009 New trial record